Characteristics of Severe Asthma Clinic Patients With Eosinophilic Granulomatosis With Polyangiitis.

Autor:	Puan Y; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore; Allergy Center, Singapore General Hospital, Singapore. Electronic address: puan.youxin@singhealth.com.sg., Ong KY; Allergy Center, Singapore General Hospital, Singapore; Division of Pharmacy, Singapore General Hospital, Singapore., Tiew PY; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Duke-NUS Medical School, Singapore., Wen Chen GX; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore., Teo NWY; Allergy Center, Singapore General Hospital, Singapore; Duke-NUS Medical School, Singapore; Department of Otorhinolaryngology - Head & Neck Surgery, Singapore General Hospital, Singapore., Low AHL; Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore., Wechsler ME; NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health, Denver, Colo., Koh MS; Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore; Allergy Center, Singapore General Hospital, Singapore; Duke-NUS Medical School, Singapore.
Jazyk:	angličtina
Zdroj:	The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.
DOI:	10.1016/j.jaip.2024.10.013
Abstrakt:	Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of antineutrophil cytoplasm antibody (ANCA)-associated vasculitis associated with varying clinical presentations and overlapping multiorgan involvement. Asthma is a predominant feature of EGPA, typically in its prodromal phase, often severe, and precedes vasculitic complications. However, there is paucity of studies describing the prevalence and characteristics of EGPA in the asthma population. Objective: To describe the clinical and serological characteristics and longitudinal therapeutic outcomes of patients with EGPA in the severe asthma (SA) cohort. Methods: A retrospective study of patients with EGPA attending the multidisciplinary SA clinic in a tertiary hospital from 2011 to 2023 was conducted. Baseline demographics, organ manifestations, biological markers, lung function, and therapeutic outcomes were assessed. Results: Twenty-three of 596 patients in the SA registry were identified to have EGPA. Median time interval between asthma and EGPA diagnosis was 10 years (range, 2.5-32 years). Almost all patients (95.7%) had peak blood eosinophil count of more than 1.0 × 10 9 /L (range, 0.47-14.08 × 10 9 /L). Upper airway involvement was the most detected manifestation in addition to asthma, followed by neuropathy and renal involvement. Patients who were treated with biologic therapy were significantly younger and had more upper airway, renal, and pulmonary involvement and lower Five Factor Score. Conclusions: The prevalence of EGPA in the SA population was 3.9% in our cohort. Its diagnosis requires high clinical suspicion in patients with SA and blood eosinophilia, prompting stringent evaluation for extrapulmonary manifestations and multidisciplinary involvement. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu